A glycosylated Fc ‐fused glucagon‐like peptide‐1 receptor agonist exhibits equivalent glucose lowering to but fewer gastrointestinal side effects than dulaglutide-Reference-Cited by-同舟云学术

A glycosylated Fc ‐fused glucagon‐like peptide‐1 receptor agonist exhibits equivalent glucose lowering to but fewer gastrointestinal side effects than dulaglutide

Published:2020-06-03 Issue:8 Volume:22 Page:1455-1468
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

An In Bok¹²^ORCID,Byun Mi Sun²,Yang Sang In²,Choi Yuri²,Woo Jung Won²,Jang Hak Chul¹,Sung Young Chul²³

Affiliation:

1. Seoul National University Bundang Hospital and Seoul National University College of Medicine Seongnam Republic of Korea

2. Research Institute, Genexine Co. Ltd. Seongnam Republic of Korea

3. Department of Life SciencePohang University of Science and Technology Pohang Republic of Korea

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14058

Reference47 articles.

1. Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm

2. Newer GLP-1 receptor agonists and obesity-diabetes

3. Glucagon like peptide-1 receptor agonists for the management of obesity and non-alcoholic fatty liver disease: a novel therapeutic option

4. Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways

5. 7. Approaches to Glycemic Treatment

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The current significance and prospects for the use of dual receptor agonism GLP-1/Glucagon;Life Sciences;2022-01